09989 HEPALINK
- 3.550
- +0.030+0.85%
HEPALINK News
The medical news is huge! Will Pharmacokinetics usher in a turning point? US pharmaceutical company contract exemption or extension for 8 years
Industry insiders believe that 8 years is enough time for relevant companies to adapt, and the implementation of this greatest uncertainty can also have a positive impact on related companies.
Closing up 42% at the end of the session, is it still too early to say that Junshengtai Pharmaceutical-B (02511) broke out of the trough?
With high investment in R&D, capital consumption will also increase. Whether the current cash can support the commercialization of Junshengtai's core products is still unknown.
Express News | Guotai Junan: Pharmaceutical industry prosperity is expected to continue to improve
Changes in Hong Kong stocks | Hapley (09989) A shares rose or stopped, and H shares once rose more than 11%, net profit to mother increased 1.33 times year-on-year in the first quarter
Hypry (09989) A-shares rose to a halt. As of press release, H shares rose 8.59% to HK$3.54, with a turnover of HK$124.367 million.
The A-share chemical pharmaceutical concept boosted the rise and fall of Chuan Ning Biotech
Glonghui, April 30 | Twining Biotech and Hypry both rose and stopped, while Alex, Tonghe Pharmaceutical, Osecon, and Borui Pharmaceuticals followed suit.
海普瑞：2023年報
Hyperion (09989) plans to renew Ernst & Young Huaming and EY as auditors
Haipuri (09989) issued an announcement. Shenzhen Haipuri Pharmaceutical Group Co., Ltd. was announced on April 29, 2024...
Hapley (09989) announced first-quarter results, net profit of 155 million yuan, up 133% year-on-year
Hapley (09989) announced its results for the first quarter of 2024, with revenue of 1,373 billion yuan, an increase of 5...
海普瑞：二零二四年第一季度報告
Hyperlink (09989.HK) held a board meeting on April 29 to consider and approve the first quarter results
On April 16, GLONGHUI (09989.HK) announced that the company will hold a board meeting on April 29, 2024 (Monday) to consider and approve the Group's first quarter results for the three months ended March 31, 2024 and their publication.
Express News | National Health Insurance Administration: Nine batches of state-organized drugs collected domestically produced generic drugs, accounting for 96%
Accelerating the integration of obstetrics and medicine! How to deal with the “two ends” problem during the differentiation period of pharmaceutical innovation? Industry figures predict future internal volume reduction
① The 7th Pharmaceutical Innovation Ecology Conference (2024 Xipai Conference) with the theme of “Reconstructing R&D and Clinical Value Transformation Ecology through the Differentiation Period” opened in Zhangjiang, Shanghai. ② How to achieve original innovation with high quality and high value, and how to efficiently commercialize post-marketing products and achieve clinical value are the focus of this conference. ③ Many participants made a judgment that domestic pharmaceutical companies will reduce internal volume in the future.
Innovative drugs continue to warm up! Joint policies in many places catalyze the strengthening of the pharmaceutical sector in Hong Kong stocks
Recently, support policies for the innovative pharmaceutical industry have been issued in many places, bringing a new market catalyst to the currently relatively deserted pharmaceutical stocks. The Hong Kong stock pharmaceutical sector is also active today.
Multiple arrows in unison! Pharmaceutical innovation support policies are coming
Recently, many places, including Beijing, Guangzhou, and Zhuhai, have successively issued relevant policies (draft for comments) to support the high-quality development of the biomedical industry or innovative pharmaceutical devices. The intensive introduction of support policies and the tight schedule have attracted great attention from the industry.
Joint Credit: Termination of the credit ratings of Hapley's entities and related debts
Joint Credit announced that since “22 Hyppry” no longer exists, United Credit will terminate the credit ratings of Hapley's entities and “22 Hyperpro” from the date of publication of this announcement, and will no longer update the rating results of the company entity and “22 Hippree”.
Featured announcements | Country Garden's March contract sales of 4.30 billion yuan; Ali Q1 purchased 524 million shares of common stock at a total price of US$4.8 billion
Midea Real Estate accumulated contract sales of 10.39 billion yuan in the first 3 months, a year-on-year decrease of 56.07%; Dongfeng Group had cumulative sales of 522,100 vehicles in the first 3 months, an increase of about 14.8% over the previous year; and Meituan awarded 602.18 million reward shares.
Shenzhen Hepalink Receives Thai Approval for Blood Clot Drug Exarane
Shenzhen Hepalink Pharmaceutical Group's (HKG:9989, SHE:002399) enoxaparin sodium injection, Exarane, has been approved by the Thailand Food and Drug Administration for sales in the market, a Tuesday
Hipry (09989.HK): EXARANE obtains approval from Thailand
On April 2, Gelonghui (09989.HK) announced that Exarane (one of the Group's leading drugs for enoxaparin sodium injections) produced by its wholly-owned subsidiary Shenzhen Tiandao Pharmaceutical Co., Ltd., has been approved for marketing by the Thai Food and Drug Administration. The announcement stated that with this approval, the ennoxaparin sodium formulation representing the Group Hypree will be sold in the Thai market, which will further increase the global market share of the Group's enoxaparin sodium preparations. The Group believes that this approval is another important achievement in implementing the international layout of the Group's pharmaceutical business, once again proving that the Group has entered overseas markets
Express News | Hyperion: Enoxaparin sodium preparation obtained Thai drug registration approval
Hapley (002399.SZ) announced its 2023 annual results, with a net loss of 783 million yuan, changing from profit to loss
According to the Zhitong Finance App, Hapley (002399.SZ) released its 2023 annual report. The company's operating income was 5.446 billion yuan, down 23.94% from the previous year; net loss attributable to shareholders of listed companies was 783 million yuan, which changed from profit to loss; net loss attributable to shareholders of listed companies after deducting non-recurring profit and loss of 780 million yuan, which changed from profit to loss; basic loss per share was 0.5338 yuan/share. During the reporting period, the company's heparin industry chain business achieved sales revenue of RMB 4.287 billion, a year-on-year decrease of 27.15%. Formulation sales remained stable, achieving sales revenue of RMB 2,979 billion
Analysis
Price Target
No Data
